Merck & Co Inc (MRK) Down 0.17%, in a Downtrend Over Past 30 Days; Pin Bar Pattern Appearing on Chart

The Hourly View for MRK

Last Updated February 19, 2021, 12:58 GMT

Currently, MRK’s price is down $-0.32 (-0.42%) from the hour prior. This is a reversal of the price action on the previous hour, in which price moved up. If you’re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 100 hour timeframe. Price action traders may also wish to note that we see a pin bar candlestick pattern on MRK. Given that we see an uptrend on the 20 hourly candle timeframe, and that such candlestick patterns often denote reversals, this may be worth noting. The moving averages on the hourly timeframe suggest a choppiness in price, as the are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.

Merck & Co Inc Daily Price Recap

The back and forth price flow continues for Merck & Co Inc, which started today off at 75.41 US dollars, down 0.17% ($0.13) from the day prior. This move happened on lower volume, as yesterday’s volume was down 27.93% from the day before — and down 40.13% from the same day the week before. Below is a daily price chart of Merck & Co Inc.

MRK

Merck & Co Inc Technical Analysis

Volatility for Merck & Co Inc has been contracting over the past two weeks relative to volatility over the past month. Whether volatility reverts will be something to watch. Trend traders will want to observe that the strongest trend appears on the 30 day horizon; over that time period, price has been moving down. Or to view things another way, note that out of the past 14 days Merck & Co Inc’s price has gone down 9 them. Also, candlestick traders! Note we see pin bar pattern appearing here as well.

Overheard Around the Web

Over on StockTwits, here’s an example of what they’re saying about MRK:

    $AIM
    WOW! CHECK THIS OUT! NEWS BEFORE THE PR.
    I ALMOST MISSED IT! SO $MRK Lambrolizumab AKA Keytruda combined with AIM Rintatolimod AKA Ampligen in phase IIa trial studies shows how well rintatolimod and pembrolizumab works in treating patients with colorectal cancer that does not respond to treatment (refractory), has spread to other places in the body (metastatic), or otherwise cannot be removed by surgery (unresectable)

    IT WAS UPDATED ON THE 9TH AND I DIDNT NOTICE.

    March 15th 2021 it begins! They know it works but how far can they push the survival rate.

    https://clinicaltrials.gov/ct2/show/NCT04119830

    So keytruda and ampligen go hand and hand fighting against cancer. MULTI BILLION DOLLAR DEALS. IT WOULD BE CHEAPER FOR MRK TO BUY THEM OUT. LETS SEE WHAT HAPPENS!

    TheLionofwallstreet